A positive Cologuard test followed by a negative colonoscopy may not always mark the end of the diagnostic journey. Researchers at DDW 2026 reported that some patients with false-positive multitarget stool DNA tests experienced a higher incidence of extracolonic aerodigestive cancers over long-term follow-up, challenging the assumption that no further workup is needed. Although the findings require additional validation, they could influence future screening strategies and post-test management for patients with unexplained positive results.
Trending
- OneOncology and OpenEvidence Partner to Improve Cancer Care Nationwide (OneOncology)
- FIT-Based Screening Linked to Drop in Colorectal Cancer Mortality (Medpage Today)
- Vedanta Biosciences Secures $60 Million in Funding and Strengthens Leadership Team Ahead of Pivotal Phase 3 Data (Business Wire)
- The physician opportunity cost nobody puts on a bill (KevinMD)
- A ‘molecular switch’ that heals the gut—and that colorectal cancer hijacks to spread (Medical Xpress)
- Why gastroenterology is especially exposed to predatory contracts, GI says (Becker’s GI & Endoscopy)
- The Microbiome Is Not a Bar Code
- Not All False-Positive Stool DNA Tests Should be Dismissed (GI & Endoscopy News)
